El valor de la selección de pacientes en NSCLC: tratamiento de segunda línea en pacientes PD-L1 positivo - page 17

Relationship Between Level of PD-L1 Expression and Outcomes

in the KEYNOTE-010 Study of Pembrolizumab versus Docetaxel

For Previously Treated, PD-L1–Positive NSCLC

Baas P et al, ASCO 2016

SEO Version

Warning.

You are currently viewing the SEO version of !text.
It has a number of design and functionality limitations.

We recommend viewing the Flash version or the basic HTML version of this publication.

1...,7,8,9,10,11,12,13,14,15,16 18,19,20,21,22,23,24,25,26,27,...43